High materiality7/10
Palvella Therapeutics price target lowered to $207 from $210 at Truist
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist lowered PVLA target to $207 from $210; current price is $154.10, with the target still above the present price.
- Target $207 (from $210); price $154.10.
- Upside remains.
Key facts
- 01
Target: $207
- 02
Posted price: $154.1
- 03
Analyst firm: Truist Financial
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.